Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230781 | 0.79 | SLC6A9 (0.59) | L3MBTL1 | |
| SCHEMBL13780494 | 0.79 | SLC6A9 (0.59) | L3MBTL1 | |
| SCHEMBL13501824 | 0.78 | KMT2A (0.69) | KMT2AHTTTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL3236708 | 0.77 | SLC6A9 (0.48) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL7893409 | 0.77 | SLC6A9 (0.68) | — | |
| SCHEMBL514434 | 0.77 | SLC6A9 (0.55) | KMT2AHTTTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL3240614 | 0.75 | SLC6A9 (0.56) | — | |
| SCHEMBL3243915 | 0.75 | SLC6A9 (0.47) | CYP3A4CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL3237783 | 0.75 | SLC6A9 (0.47) | — | |
| SCHEMBL3239398 | 0.74 | SLC6A9 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227629-A1 | COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | GLAXO GROUP LIMITED | 2009-09-10 | — | — | US | claimed |
| US-20090227629-A1 | COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | GLAXO GROUP LIMITED | 2009-09-10 | — | — | US | disclosed |
| US-20090227629-A1 | COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | GLAXO GROUP LIMITED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227629-A1 | COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | SLC18A2, SLC6A3, SLC6A2 | KMT2A 1191/4885HTT 223/4885TSHR 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.